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Interleukin- (IL-)10 and IL-13 play important roles in Th2 cell diﬀerentiation and production of autoantibodies in patients with
(SLE). However, the mechanisms leading to IL10 and IL13 overexpression in SLE patients are not well understood. In this study,
we conﬁrm that the levels of both IL10 and IL13 mRNA in CD4+ Tc e l l sa n do fs e r u mIL10 and IL13 proteins are increased in SLE
patients. We show that the DNA methylation levels within IL10 and IL13 gene regulatory domains are reduced in SLE CD4+ Tc e l l s
relative to healthy controls and negatively correlate with IL10 and IL13 mRNA expression. Moreover, treating healthy CD4+ Tc e l l s
with the demethylating agent 5-azacytidine (5-azaC) increased IL10 and IL13 mRNA transcription. Together, our results show that
promoter methylation is a determinant of IL10 and IL13 expression in CD4+ T cells, and we propose that DNA hypomethylation
leads to IL10 and IL13 overexpression in SLE patients.
1.Introduction
Systemic lupus erythematosus (SLE) is a rheumatic autoim-
mune disease characterized by various immunological
abnormalities, including T lymphocyte autoreactivity and
the activation of polyclonal B cells, leading to the production
of autoantibodies such as antinuclear antibodies (ANA),
rheumatoid factor (RF), and anticardiolipin antibodies
(aCL) [1]. Defective immune regulation seems to stem from
a functional imbalance of T lymphocyte subsets [2]. Within
the CD4+ T helper (Th) of patients with SLE, activated
Th2 cells overproduce interleukin-6 (IL-6), IL-10, IL-13,
and tumor necrosis factor-a whereas Th1 cells underproduce
IL-2, interferon-gamma (IFN-γ), and transforming growth
factor-β [3–5]. IL-10 is a potent stimulator of B lymphocytes
aswellasapowerful inhibitor of antigen-presenting cellsand
T lymphocyte functions [6]. Peripheral blood mononuclear
cells (PBMCs) from SLE patients express high levels of IL10
mRNAandprotein,andthelevelofserumIL-10iscorrelated
with disease activity and severity [7–11]. IL-13 is a cytokine
secreted by many cell types but especially Th2 cells. Levels of
IL-13 in patients with active SLE are signiﬁcantly increased
and are correlated with disease activity, as deﬁned by the SLE
diseaseactivityindexofSLE(SLEDAI)[12].However,littleis
known about the mechanisms underlying the overexpression
of these cytokines in SLE patients.
Previous studies have demonstrated that abnormal
hypomethylation of CD4+ Tc e l lD N Ac a nc o n t r i b u t e
to the pathogenesis of lupus-like diseases [13], and this
phenomenon is associated with reduced expression and
activity of the DNA methyltransferase enzyme DNMT1 in
patient CD4+ Tc e l ls a m p l e s[ 14, 15]. The hypomethylation
of speciﬁc DNA loci in T cells from SLE patients results
in the upregulation of methylation-sensitive autoimmune-
related genes, such as CD11a (ITGAL), CD70 (TNFSF7),
CD40 ligand (TNFSF5), and perforin (PRF1) [16–20]. These
data and others show that DNA methylation and chromatin
structure can inﬂuence the expression of SLE-related genes.
We thus hypothesized that the Th2 cytokines IL10 and IL13
are upregulated in SLE due to aberrant DNA methylation of
theirpromoterregions inCD4+ Tcells,therebycontributing
to the activation of the humoral immune machinery and
triggering lupus disease activity.2 Journal of Biomedicine and Biotechnology
Table 1: Patient demographics, medications.
Patient Sex/Age SLEDAI score Medication
1F / 3 5 6Pred 20mg/d
2F / 3 3 4None
3F / 2 2 1 0 Pred 40mg/d
4F / 2 7 6Tria 8mg/d
5F / 2 9 6None
6F / 2 6 1 6 TG 40mg/d
7F / 3 2 1 2 Pred 35mg/d
8F / 1 8 8None
9F / 2 4 4Pred 10mg/d
10 F/30 11 Pred 20mg/d
11 F/31 16 Pred 40mg/d
12 F/23 6 Tria 16 mg/d
13 F/43 10 Pred 20mg/d
14 F/41 14 Pred 30mg/d
15 F/29 10 Pred 25mg/d
F, female; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index;
Pred: Prednisone; Tria: Triamcinolone; TG: Tripterygium Glycosides.
To test this hypothesis, we examined the DNA methyla-
tion status of the IL10 and IL13 genes in CD4+ T cells. We
found that the methylation of C/G pairs within the IL10 and
IL13 promoter was signiﬁcantly reduced in T cells from SLE
CD4+ Tcellscomparedwithhealthycontrolsamples,andthe
methylation status was inversely correlated to the levels of
IL10 and IL13 transcripts and proteins, as well as the severity
of SLE. Furthermore, we found that the treatment of healthy
CD4+ Tcellswiththemethylationinhibitor5-azacytidine(5-
azaC) induced IL10 and IL13 expression to levels similar to
those observed in SLE CD4+ T cells. These results indicate
an important role of DNA methylation in regulating the
expression of the Th2 cytokines in SLE.
2.MaterialsandMethods
2.1. Subjects. Patient demographics and treatment regimens
are shown in Table 1. SLE patients (mean ± SD age 30 ± 6
years) were recruited from outpatient clinics of the Second
Xiangya Hospital, Central South University. All patients
fulﬁlled at least 4 of the SLE classiﬁcation criteria of the
American College of Rheumatology [21]. Lupus disease
activity was assessed using the SLE Disease Activity Index
(SLEDAI) [22]. Healthy controls (mean ± SD age 26 ±
4 years) were recruited from medical staﬀ at the Second
Xiangya Hospital. This study was approved by the human
ethics committee of the Central South University Xiangya
Medical School, and written informed consent was obtained
from all subjects. Patients and controls were age and sex
matched in all experiments.
2.2. Isolation and Culture of CD4+ TC e l l s . A total of 60mL
ofvenousperipheralblood waswithdrawnfromeachpatient
and control subject and preserved with heparin. PBMCs
were isolated by density gradient centrifugation, and CD4+
T cells were isolated by positive selection using CD4 beads,
according to the protocol provided by the manufacturer
(Miltenyi, Germany). The purity of enriched CD4+ Tc e l l s
was evaluated by ﬂow cytometry and was generally higher
than 95%, where indicated PBMCs were stimulated with
phytohemagglutinin (PHA), and then cultured with 1μM5 -
azaC(Sigma-Aldrich, USA)in RPMI1640/10% FCS/IL-2for
anadditional72hours.Afterthat,CD4+ Tcellswereisolated
from treated PBMCs using CD4 beads. This protocol has
been shown to be optimal for inducing expression of other
methylation-sensitive T cell genes [16, 18].
2.3. RNA Isolation and Real-Time Quantitative RT-PCR.
Total RNA was isolated from CD4+ T cells using the RNeasy
minikit (Qiagen, Germany). Real-time quantitative RT-PCR
wasperformedusingaRotor-Gene3000(Qiagen,Germany),
a n dm R N Al e v e l sw e r eq u a n t i ﬁ e du s i n gt h eO n eS t e pP r i m e -
Script RT-PCR Kit (TaKaRa Biotech [Dalian] Co., China). A
dilution series of sample RNA was also included to generate
a standard curve used to calculate the relative concentrations
of transcript present in each sample. Negative controls (in
w h i c hw a t e rw a ss u b s t i t u t e df o rR N A )w e r er u nf o re a c h
sample. β-actin was also ampliﬁed and used as a loading
control. The speciﬁc primers used for ampliﬁcation of
IL10 were forward, 5
 -TGAGAACAGCTGCACCCACTT-3
 
and reverse, 5
 -TCGGAGATCTCGAAGCATGTTA-3
 ; IL13:
forward, 5
 -CAATGGCAGCATGGTATG-3
  and reverse, 5
 -
ATCCTCTGGGTCTTCTCG-3
 ;a n dβ-actin:f o r w a r d ,5
 -
CGCGAGAAGATGACCCAGAT-3
  and reverse, 5
 -GCA-
CTGTGTTGGCGTACAGG-3
 .
2.4. Enzyme-Linked Immunosorbent Assays (ELISAs). IL-10
and IL-13 protein concentrations in the serum from SLE
patients and healthy controls were measured using an ELISA
kit (R&D, USA), following the protocol of manufacturer.
Optical density (OD) values were read at 450nm using
EL × 800 Absorbance Microplate Reader (BioTek, USA).
2.5. Genomic DNA Extraction and Bisulﬁte Sequencing.
Genomic DNA was isolated from CD4+ T cells using the
TIANamp Genomic DNA kit (Tiangen Biotech, Beijing,
China). Bisulﬁte conversion was performed using the
EpiTect Bisulﬁte Kit (Qiagen, Germany). The 192bp (+3119
to +3310) IL10 enhancer and 290bp (−2334 to −2045)
IL13 promoter fragments contain some important
transcription factors binding sites such as STAT5, SP1,
and AP-2 predicted using the bioinformatics software
Matinspector (http://www.genomatix.de/) and PROSCAN
(http://www-bimas.cit.nih.gov/molbio/proscan/).
Importantly, these regions encompass enriched CG pairs.
These fragments were ampliﬁed by nested PCR and cloned
into pGEM-T vector (Promega, USA). Five independent
clones were sequenced for each of the ampliﬁed fragments.
Primers used are described in Table 2.
2.6. Statistical Analysis. The Student’s t-test for equality of
means was used to compare values. P-values of less than .05Journal of Biomedicine and Biotechnology 3
Table 2: Nest-PCR primers for Bisulﬁte sequencing.
Gene Amplication location Sequence (5
 –3
 )
round I: forward
(+3063 to +3088bp) TTGGGGGTTTAGTTTAGATTTTTTAG
IL10 round I: reverse
(+3331 to +3307bp) TTCACACCCCCTAATATTAACACTC
round II: forward
(+3119 to +3143bp) ATTTAATTTGGAGTTGGTTTAAGTT
round II: reverse
(+3310 to +3285bp) ACTCTATACAATATCTATCCCCAACC
round I: forward
(−2425 to −2401bp) TTGATTGGGTATTATGTTTTTGTTA
round I: reverse
(−1537 to −1561bp) AACTACCTTAATCTATACAACTCCC
IL13 round II: forward
(−2334 to −2312bp) GAGGAAGGGAGGTTTTAATTTTA
round II: reverse
(−2045 to −2069bp) ACCCTAAAAAATAATCTCCAAAAAC
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Figure 1: Serum IL-10 and IL-13 protein levels in SLE patients (n = 15) and healthy controls (n = 15). The mean concentration of IL-10
(a) and IL-13 (b) were detected by ELISA (P = .005; P = .007).
were considered signiﬁcant. All analyses were performed
with SPSS Version 13.0 software.
3. Results
3.1. Serum IL-10 and IL-13 Levels in SLE Patients and
Healthy Controls. We isolated the serum from peripheral
blood samples of 15 SLE patients and 15 healthy controls
and then measured the concentration of IL-10 and IL-13 by
ELISA. As shown in Figures 1(a) and 1(b),s e r u mp r o t e i n
levels were signiﬁcantly increased in SLE patients.
3.2. IL10 and IL13 Transcription Levels in SLE CD4+ TC e l l s
Correlate withDisease Activity of SLE. Real-time quantitative
RT-PCR was used to detect the mRNA level of IL10 and IL13
inCD4+ Tcellsfrom15SLEpatientsand15healthycontrols.
As shown in Figures 2(a) and 2(b), the mean expression
levels of IL10 and IL13 relative to β-actin were signiﬁcantly
elevated in patient samples compared to healthy controls.
Furthermore, we analyzed the relationship between IL10 and
IL13 mRNA levels in CD4+ T cells in individual samples
with patient disease activity and found a positive correlation
between them (Figures 2(c) and 2(d)).
3.3. Regulatory Element Methylation Status in SLE CD4+
T Cells Correlates with IL10 and IL13 Expression. Previous
studies have demonstrated that DNA methylation and
chromatin structure participate in the regulation of Th2
cytokine genes transcription during Th cell diﬀerentiation
[23].TotestwhetherchangesinDNAmethylationcontribute4 Journal of Biomedicine and Biotechnology
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Figure 2: IL10 and IL13 mRNA expression in CD4+ T cells from SLE patients (n = 15) and healthy controls (n = 15) and the relationship
between expression and disease activity. (a) and (b) IL10 and IL13 mRNA levels in CD4+ T cells were measured by quantitative real-time
PCRandnormalizedtoβ-actin(SLEversushealthycontrol,P = .007andP = .006,respectively).(c)InSLEpatients,IL10 mRNAexpression
correlated (r = 0.746) with SLEDAI score (P = .001). (d) IL13 mRNA expression also correlated with disease activity (r = 0.628, P = .012).
to IL10 overexpression in SLE CD4+ T cells, we detected the
methylation status of CG pairs in 192bp (position +3119 to
+3310) CpG inland within the intron 4 enhancer element of
the IL10 gene containing the transcription activator STAT5
binding site [24]. Ampliﬁed fragments were cloned and ﬁve
clones were sequenced for each ampliﬁcation product from
each subject (SLE patients, n = 10; healthy controls, n = 10).
Figure 3(a) shows the average methylation of each of the 8
CG pairs within the region. Although the mean methylation
status of most CG pairs appeared somewhat less methylated
in the patient group, there was no statistically signiﬁcant
diﬀerence in the overall combined mean methylation status
when compared to controls (0.615 ± 0.251 versus 0.375 ±
0.261; P = .083). However, the CG pair at position +3281
was unmethylated in both lupus CD4+ T cells and healthy
controls, and when this pair was removed from the overall
combined average, the average mean methylation status of
theother7CGpairs(positions +3144,+3162,+3170,+3200,
+3229, +3261, and +3265) was found to be signiﬁcantly
lower in lupus CD4+ T cells than in controls (Figures 3(a)
and 3(b)). Moreover, we found that the average methylation
status of the 7 methylated CG pairs within the intron 4 CpG
island was negatively correlated with IL10 mRNA expression
(Figure 3(c)).
We next investigated the status of a CpG island within
a distal promoter region for the IL13 gene in CD4+ T
cells from SLE patients (n = 10) and healthy controls
(n = 10). Figure 4(a) shows the mean methylation status
of each of the 20 CG pairs within this region. We found
that the average methylation status of a group of six
methylation sites at the proximal end of the detected element
(position −2100 to −2076) was signiﬁcantly lower in the
SLE group compared to controls (Figure 4(b)) although
there was no signiﬁcant diﬀerence in the overall average
methylation level of all 20 CG pairs (0.592 ± 0.206 versus
0.520 ± 0.237; P = .314). Furthermore, we found that
the average methylation status of the 6 proximal-end CG
pairs (−2100, −2098, −2090, −2085, −2081, and −2076)
was inversely correlated with the IL13 mRNA expression
(Figure 4(c)).Journal of Biomedicine and Biotechnology 5
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Figure 3: IL10 enhancer methylation patterns in CD4+ T cells from SLE patients and healthy controls. (a) The mean methylation status
for each of the 8 CG pairs within intron 4 of the IL10 locus in CD4+ T cells from healthy controls (n = 10; upper panel) and SLE patients
(n = 10; lower panel). (b) The combined average methylation status of 7 CG pairs (positions +3144, +3162, +3170, +3200, +3229, +3261,
and +3265) in IL10 intron 4 in SLE CD4+ T cells was lower than healthy controls (P = .036). (c) Average IL10 promoter DNA methylation
status correlated (r =− 0.432) with relative mRNA level in SLE patients (P = .040).
3.4. Treatment of Healthy CD4+ T Cells with 5-azaC Enhances
IL10 and IL13 mRNA Transcription. Our previous studies
have demonstrated that treating CD4+ T cells from healthy
controls with DNA methyltransferase inhibitors such as
5-azaC or PD98059 decreases the DNA methylation level
of certain SLE-related autoimmune genes, leading to their
upregulation [16–19]. In this study, we asked whether 5-
azaC could aﬀect IL10 and IL13 gene expression in T cells
from healthy controls. We treated CD4+ T cells with 1μM5 -
azaC for 72 hours and detected the mRNA level of IL10 and
IL13 by real-time quantitative RT-PCR. The results showed
that IL10 and IL13 increased signiﬁcantly in the presence of
5-azaC compared with negative controls (Figures 5(a) and
5(b)), suggesting that methylation levels are critical for the
normal regulation of IL10 and IL13 in CD4+ T cells.
4. Discussion
The imbalance between Th1 and Th2 cells observed in
SLE patients is thought to be responsible for provoking
a deregulation of cytokine production that contribute to
polyclonal B-cell activation observed in SLE patients [1,
3]. In support of this, it has been demonstrated that
abnormally high IL-10 secretion by monocytes and lym-
phocytes is responsible for the heightened production of
immunoglobulins of SLE patients [25]. IL-10 production
is also enhanced in patients with rheumatoid arthritis
(RA) or Sj¨ ogren’s syndrome, two disorders characterized
by prominent B lymphocyte hyperactivity that results in
the hyperproduction of immunoglobulins and the increased
synthesis of autoantibodies [9]. In this study, we conﬁrmed6 Journal of Biomedicine and Biotechnology
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Figure 4: IL13 promoter methylation patterns in CD4+ T cells from SLE patients and healthy controls. (a) The mean methylation status for
each of the 20 CG pairs within the distal promoter of the IL13 locus in CD4+ T cells from healthy controls (n = 10; upper panel) and SLE
patients (n = 10; lower). The boxed area indicates the region (positions −2100, −2098, −2090, −2085, −2081, and −2076) with reduced
methylation in SLE patients. (b) The combined average methylation status of the 6 hypomethylated CG pairs in the distal promoter of IL13
in SLE CD4+ T cells was reduced compared with the combined average methylation status of these positions in healthy controls (P = .020).
(c) Average IL13 promoter (position −2100 to −2076) DNA methylation status correlated (r =− 0.598) with relative mRNA level in SLE
patients (P = .006).
that IL10 is overexpression in CD4+ T cells isolates from SLE
patients compared to healthy controls and IL10 expression
positively correlates with disease activity, consistent with
previous studies measuring IL10 expression in SLE PBMCs
[7–11], suggesting IL-10 plays an important role in the
development of SLE.
IL-13 is produced mainly by Th2 cells and is involved
in Th2 diﬀerentiation [26–28]. It also functions in Th2
cells to stimulate the proliferation and diﬀerentiation of B
lymphocytes inducing IgM, total IgG [26], IgG4, and IgE
[27] synthesis, but not IgA production [26, 27]. Herein
we found that serum levels of IL-13 in SLE patients are
signiﬁcantly elevated, in agreement with previous studies
[4]. We further demonstrated that IL13 transcription in
SLE CD4+ T cells correlated with patient disease activity.
These results suggest that both IL-10 and IL-13 play critically
important roles in the etiology of SLE and possibly other
rheumatic autoimmune disorders; however the mechanism
leading to their overproduction is unknown.
Previous studies have conﬁrmed that global genomic
methylation is reduced in lupus CD4+ T cells compared with
healthy controls and, furthermore, the hypomethylation of
speciﬁc promoter regions contributes to the overexpression
of some SLE-related genes such as CD11a, CD70, CD40L,
and Perforin [13, 16–20]. To understand the mechanism(s)
underlyingtheoverexpressionof IL10 andIL13inSLECD4+
T cells, we investigated the methylation status of CpG islands
within known regulatory domains for these genes. We found
that the methylation status of CG pairs within the enhancer
intron 4 of the IL10 genomic locus and within the distalJournal of Biomedicine and Biotechnology 7
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Figure 5: Treatment of healthy CD4+ T cells with 5-azaC promotes IL10 and IL13 mRNA transcription. mRNA expression levels of IL10 (a)
and IL13 (b) were measured by quantitative real-time PCR and normalized to β-actin. Treatment with 5-azaC results in a 2.6-fold increase
of IL10 and a 5.7-fold increase of IL13, relative to untreated controls (P = .017 and P = .025, resp.).
IL13 promoter was signiﬁcantly reduced in patient samples
relative to healthy controls. Furthermore, we found that the
averagemethylationlevelofhypomethylatedCGpairswithin
these regions negatively correlated with mRNA transcription
levels. We further showed that treating CD4+ Tc e l l sf r o m
healthy controls with the DNMT inhibitor 5-azaC led to a
signiﬁcant increase in IL10 and IL13 transcription, similar to
what has been shown for other SLE-related autoimmunity
genes, such as CD11a [16], Perforin [17], CD70 [18], and
CD40L [19].
Ap r e v i o u ss t u d ys u g g e s t e dt h a tIL13 expression in Th2
cells is regulated by the methylation status of a region in
the proximal promoter encompassing three putative GATA-
3 binding sites [23]. This prompted us to investigate the
methylation status of the CpG sites around the transcrip-
tional start site of IL13 in T cells. However, we found that
all 10 CG sites within the proximal promoter are heavily
methylated in both SLE and healthy control CD4+ Tc e l l s
(data not shown), suggesting that the upregulation of IL13 in
SLE patients is not dependent on the demethylation of this
region. In contrast, we found that the methylation status of 6
CG pairs (out of a total of 20) within the distal promoter was
aﬀected in SLE patients and that demethylation of this sites
correlated with IL13 expression in SLE and healthy control
CD4+ T cells, suggesting that methylation of these particular
sites is an important indicator of SLE disease activity.
DNA methylation modiﬁes gene expression through at
least three mechanisms. Methylation of target sequences
prevents the binding of some transcriptional activators,
such as Sp1 and AP-2, thereby suppressing expression [29].
Methylcytosinebindingproteinscanalsopreventthebinding
of transcription factors and can suppress gene expression
from a distance [30]. Methylcytosine binding proteins
also attract chromatin remodeling complexes that modify
adjacent histones, resulting in a condensed nucleosome
structure, making the locus inaccessible to transcription
factors [31]. The methylation-sensitive regions within IL10
intron 4 and the distal promoter of IL13 both contain
potential Sp1, AP-2, and STAT5 binding sites predicted
using bioinformatics software Matinspector and PROSCAN
(Version 1.7). Moreover, it has been demonstrated that the
expression of cytokine genes during T-cell diﬀerentiation
is regulated by acetylation- and methylation-dependent
chromatin structural changes [32]. Thus no one mechanism
can be ruled out, and further experiments will need to be
performed in order to elucidate the underlying cause of
methylation-dependentIL10andIL13upregulationinCD4+
T cells of patients with SLE.
The reasons why the regulatory element of IL10 and IL13
are hypomethylation remain unclear. Akahoshi reported
that there was no diﬀerence in the Th1:Th2 ratio between
SLE patients with/without proteinuria and healthy controls,
suggesting overexpression and hypomethylation of IL10 and
IL13 may be not associated with the number of Th1 and Th2
cells [2]. Our recent studies have found that many factors,
such as aberrant expression of speciﬁc transcriptional factor
RFX1 and nucleus protein Gadd45a, may be involved in
regulating the methylation status of methylation-sensitive
genes in lupus CD4+ T cells [33, 34].
In summary, disease activity-related increases of IL10
and IL13 expression in CD4+ T cells from SLE patients are
associated with demethylation of speciﬁc CpG islands within
IL10 enhancer and IL13 promoter regions. These ﬁndings
provide a basis for the design of a new therapy aimed at
reversing the epigenetic alternations of gene expression in
human SLE patients.
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